Article
Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 May 2017
Lesurf R, Griffith O L, Griffith M, Hundal J, Trani L, Watson M A, Aft R, Ellis M J, Ota D, Suman V J, Meric-Bernstam F, Leitch A M, Boughey J C, Unzeitig G, Buzdar A U, Hunt K K, Mardis E R
Abstract excerpt
Background: HER2 (ERBB2) gene amplification and its corresponding overexpression are present in 15-30% of invasive breast cancers. While HER2-targeted agents are effective treatments, resistance remains a major cause of death. The American College of Surgeons Oncology Group Z1041 trial (NCT00513292) was designed to compare the pathologic complete response (pCR) rate of distinct regimens of neoadjuvant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.